CROHN’S DISEASE TREATMENT MARKET ANALYSIS

Crohn’s Disease Treatment Market, by Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI1237
Pages :150
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Crohn’s Disease Treatment Market: Key Developments

On June 17, 2022, AbbVie Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).

In March 2022, Tiziana Life Sciences, a biotechnology company, had commenced a Phase Ib clinical trial of oral enteric-coated capsules of foralumab (TZLS-401), a monoclonal antibody (mAb), in mild-to-moderate Crohn’s disease (CD) patients.